NICE rejects Astellas’ Xospata in AML, queries MSD’s Keytruda evidence in HNSCCNICE has been busy with announcements today, rejecting Astellas’ Xospata for a certain type of acute myeloid leukaemia Share XNICE rejects Astellas’ Xospata in AML, queries MSD’s Keytruda evidence in HNSCChttps://pharmaphorum.com/news/nice-rejects-astellas-xospata/
Transgene starts trials of ‘digital’ cancer vaccine with NECUndeterred by two clinical failures for its cancer immunotherapies in 2019, Transgene has kicked off the New Year Share XTransgene starts trials of ‘digital’ cancer vaccine with NEChttps://pharmaphorum.com/news/transgene-starts-trials-of-digital-cancer-vaccine-with-nec/
Scotland backs AZ’s Lynparza for first-line ovarian cancer maintenanceThe Scottish Medicines Consortium (SMC) has backed routine funding of AstraZeneca and MSD’s Lynparza as a maintenance treatment Share XScotland backs AZ’s Lynparza for first-line ovarian cancer maintenancehttps://pharmaphorum.com/news/scotland-backs-azs-lynparza-for-first-line-ovarian-cancer-maintenance/
NICE backs Lynparza across the board for BRCA+ovarian cancerAstraZeneca and MSD’s Lynparza has become the first PARP inhibitor to be recommended for all lines of maintenance Share XNICE backs Lynparza across the board for BRCA+ovarian cancerhttps://pharmaphorum.com/news/nice-backs-lynparza-across-the-board-for-brca-ovarian-cancer/
GSK’s PARP drug Zejula approved in wider ovarian cancer populationThe FDA has approved GlaxoSmithKline’s Zejula (niraparib) in a wider ovarian cancer indication, the first time a PARP Share XGSK’s PARP drug Zejula approved in wider ovarian cancer populationhttps://pharmaphorum.com/news/gsks-parp-drug-zejula-approved-in-wider-ovarian-cancer-population/
New price gets Clovis’ PARP inhibitor on the CDFNICE has reversed its decision on Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) and will allow the drug to Share XNew price gets Clovis’ PARP inhibitor on the CDFhttps://pharmaphorum.com/news/new-price-gets-clovis-parp-inhibitor-on-the-cdf/
ESMO 2019 – new data could unlock bigger market for PARP inhibitorsAstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as Share XESMO 2019 – new data could unlock bigger market for PARP inhibitorshttps://pharmaphorum.com/news/esmo-2019-new-data-could-unlock-bigger-market-for-parp-inhibitors/
As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer dataGlaxoSmithKline and AstraZeneca will go head-to-head with new data on their PARP inhibitor drugs this weekend, as the Share XAs ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer datahttps://pharmaphorum.com/news/as-esmo-opens-its-doors-gsk-and-az-prep-all-comer-ovarian-cancer-data/
AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmentAstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this Share XAZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmenthttps://pharmaphorum.com/news/az-msd-parp-inhibitor-ovarian-cancer/
